A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Article Details

Authors
Mariane Teodoro Fernandes MD, Jacob J Adashek BA, Carmelia Maria Noia Barreto MD, Ana Cláudia Barbin Spinosa MD, Barbara de Souza Gutierres MSc, Gilberto Lopes MD, MBA, FAMS, Auro del Giglio MD, PhD, Pedro Nazareth Aguiar Jr MD, MSc

Article Type
Review

DOI
10.7573/dic.212555

Related Articles

Article Page

Abstract

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.

Keywords: breast cancer, targeted therapy, endocrine therapy, cyclin-dependent kinase 4, cyclin-dependent kinase 6.

Citation: Fernandes MT, Adashek JJ, Noia Barreto CM, Barbin Spinosa AC, de Souza Gutierres B, Lopes G, del Giglio A, Aguiar PN Jr. A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context 2018; 7: 212555. DOI: 10.7573/dic.212555

Contributions: MT Fernandes, JJ Adashek, CM Noia Barreto and AC Barbin Spinosa wrote the manuscript. B de Souza Gutierres and A del Giglio reviewed the text. PN Aguiar and G Lopes developed the review and checked all text.

Disclosure and potential conflicts of interest: The authors declare that there is no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/10/dic.212555-COI.pdf

Acknowledgments: Pui San Tan highlighted new data to be inserted in the review.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2018 Fernandes MT, Adashek JJ, Noia Barreto CM, Barbin Spinosa AC, de Souza Gutierres B, Lopes G, del Giglio A, Aguiar PN Jr. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Fernandes MT, Adashek JJ, Noia Barreto CM, Barbin Spinosa AC, de Souza Gutierres B, Lopes G, del Giglio A, Aguiar PN Jr. https://doi.org/10.7573/dic.212555. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Citation: Fernandes MT, Adashek JJ, Noia Barreto CM, Barbin Spinosa AC, de Souza Gutierres B, Lopes G, del Giglio A, Aguiar PN Jr. A paradigm shift for the treatment of hormone receptorpositive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context 2018; 7: 212555. DOI: 10.7573/dic.212555

Article URL: https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors

Correspondence: Pedro Nazareth Aguiar Jr, Faculdade de Medicina do ABC, Rua Correia Dias, 171, Paraíso, São Paulo/SP, 04104-000, Brazil. pnajpg@hotmail.com

Provenance: invited; externally peer reviewed.

Submitted: 3 September 2018; Peer review comments to author: 3 October 2018; Revised manuscript received: 8 October 2018; Accepted: 9 October 2018; Publication date: 5 November 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF